Rights IssueJun 16, 2026, 05:06 PM
Vivos Therapeutics Plans Rights Offering to Shareholders
AI Summary
Vivos Therapeutics, Inc. announced its intention to file a registration statement for a proposed rights offering. The offering would distribute transferable subscription rights to shareholders as a dividend. Each right is expected to allow the holder to purchase one share of common stock at an exercise price based on a floor of $1.25 or a premium to the market price. The rights are intended to be listed for trading and exercisable for nine months, with a potential subsequent right upon exercise. The offering is subject to SEC effectiveness, shareholder approval, and other conditions.
Key Highlights
- Vivos Therapeutics announces intent to file registration statement for a proposed rights offering.
- Shareholders may receive transferable subscription rights as a dividend.
- Each right expected to allow purchase of one share of common stock.
- Exercise price expected to be the greater of $1.25 or 20% above market price on day before record date.
- Rights expected to be exercisable for nine months.
- Upon exercise, holder expected to receive a subsequent nine-month trading right.
Price Impact
More from VVOS